S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. by Lu, Jie et al.
Lawrence Berkeley National Laboratory
Recent Work
Title
S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome 
neural progenitors.
Permalink
https://escholarship.org/uc/item/57d15061
Journal
PloS one, 6(7)
ISSN
1932-6203
Authors
Lu, Jie
Esposito, Giuseppe
Scuderi, Caterina
et al.
Publication Date
2011
DOI
10.1371/journal.pone.0022126
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
S100B and APP Promote a Gliocentric Shift and Impaired
Neurogenesis in Down Syndrome Neural Progenitors
Jie Lu1, Giuseppe Esposito2, Caterina Scuderi2, Luca Steardo2, Laurent C. Delli-Bovi3, Jonathan L. Hecht4,
Bryan C. Dickinson5, Christopher J. Chang5,6, Takashi Mori7, Volney Sheen1*
1Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, 2Department of Human
Physiology and Pharmacology ‘‘V. Erspamer’’, Faculty of Pharmacy, University of Rome ‘‘La Sapienza’’, Piazzale Aldo Moro, Rome, Italy, 3Department of Obstetrics and
Gynecology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 4Department of Pathology, Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, 5Howard Hughes Medical Institute, Department of Chemistry, University of
California, Berkeley, California, United States of America, 6Howard Hughes Medical Institute, University of California, Berkeley, California, United States of America,
7Departments of Biomedical Sciences and Pathology, Saitama Medical Center and Saitama Medical University, Kawagoe, Saitama, Japan
Abstract
Down syndrome (DS) is a developmental disorder associated with mental retardation (MR) and early onset Alzheimer’s
disease (AD). These CNS phenotypes are attributed to ongoing neuronal degeneration due to constitutive overexpression of
chromosome 21 (HSA21) genes. We have previously shown that HSA21 associated S100B contributes to oxidative stress and
apoptosis in DS human neural progenitors (HNPs). Here we show that DS HNPs isolated from fetal frontal cortex
demonstrate not only disturbances in redox states within the mitochondria and increased levels of progenitor cell death but
also transition to more gliocentric progenitor phenotypes with a consequent reduction in neuronogenesis. HSA21
associated S100B and amyloid precursor protein (APP) levels are simultaneously increased within DS HNPs, their secretions
are synergistically enhanced in a paracrine fashion, and overexpressions of these proteins disrupt mitochondrial membrane
potentials and redox states. HNPs show greater susceptibility to these proteins as compared to neurons, leading to cell
death. Ongoing inflammation through APP and S100B overexpression further promotes a gliocentric HNPs phenotype.
Thus, the loss in neuronal numbers seen in DS is not merely due to increased HNPs cell death and neurodegeneration, but
also a fundamental gliocentric shift in the progenitor pool that impairs neuronal production.
Citation: Lu J, Esposito G, Scuderi C, Steardo L, Delli-Bovi LC, et al. (2011) S100B and APP Promote a Gliocentric Shift and Impaired Neurogenesis in Down
Syndrome Neural Progenitors. PLoS ONE 6(7): e22126. doi:10.1371/journal.pone.0022126
Editor: Olivier Baud, Hoˆpital Robert Debre´, France
Received May 11, 2011; Accepted June 15, 2011; Published July 11, 2011
Copyright:  2011 Lu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants to V.L.S. from NINDS 1R01NS063997, NICHD 1R21HD054347, and the Harvard Neurodiscovery Center. V.L.S. is a
Doris Duke Clinical Scientist Development Award recipient and Alzheimer’s Association New Investigator. C.J.C. is an Investigator at the Howard Hughes Medical
Institute and thanks the NIH (GM 79465) for research support. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vsheen@bidmc.harvard.edu
Introduction
Down syndrome (DS) arises from a triplication of genes on
chromosome 21 (HSA21) and is characterized by neurological
complications including mental retardation and early onset
Alzheimer’s disease (AD) [1]. The reduced brain size and sim-
plified gyral patterning are thought to be major determinants of
the cognitive impairment in DS individuals. At the cellular level,
DS brains show prolongation in the cell cycle length of neural
progenitors [2,3], as well as increased oxidative stress and
mitochondrial dysfunction within neurons [3,4,5]. These findings
would suggest that both abnormalities in proliferation and pro-
gressive neuronal loss through apoptosis contribute to the devel-
opmental neuropathology in DS.
Studies using DS human neural progenitors (HNPs) have
proposed several mechanisms underlying the loss in neuronal
numbers in DS brain. Expression profiling of 18 week gestational
age (W GA) DS HNPs followed by in vitro studies are able to
demonstrate constitutive overexpression of HSA21 associated
S100B, leading to increased reactive oxygen species (ROS) for-
mation, activation of stress response kinases, and cell death [6].
Comparison of the differentially expressed genes in DS versus
wild type (WT) HNPs at 13W GA demonstrates that progenitors
exhibited impairments in interneuron neurogenesis, related to
increased expression of the transcription factor COUP-TF1/
NR2F1 and downregulation of the interneuron related genes
DLX1, DLX2 and DLX5 [7]. Finally, other studies have reported
a decrease in neuroectodermal genes such as Nestin and Tubb3 in
DS HNPs with a corresponding increase in mesodermal genes
such as Snail1 and Pitx2, indicating that HSA21 genes such as
DYRK1A could regulate various embryonic lineages [8].
Interactions between HSA21-associated S100B and amyloid
precursor protein (APP) might effect neural progenitor develop-
ment and contribute to the cognitive impairment in DS. Recent
studies have shown deleterious effects from the constitutive over-
expression of the HSA21-associated S100B in DS HNPs. Soluble
S100B activates the receptor for advanced glycation endproducts
(RAGE), leading to generation of reactive oxygen species (ROS),
and induction of MAP kinases, including JNK. JNK activation
induces Dickopff-1 expression that in turn promotes GSK3ß
phosphorylation and tau hyperphosphorylation [6,9]. The HSA21
associated gene APP contributes to the pathological deposition of
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beta amyloid (Ab) in the brain [10]. Amyloid-forming pro-
teins such as Ab both accelerate tau hyperphosphorylation and
represent a second group of RAGE ligand that could further
enhance S100B-mediated cell injury [11]. These observations raise
the possibility that these two contiguous genes on HSA21 might
influence DS progenitor survival and proliferation through a
common shared pathway.
Here we show that constitutive overexpression of HSA21 asso-
ciated S100B and APP promotes a deleterious, cyclical pathway
involving synergistic overproduction and hypersecretion of both
proteins, altered mitochondrial redox states, cell injury and
neuronal death. The ongoing neural injury and inflammation
further promote a gliocentric progenitor phenotype and indicate
that DS HNPs inherently differ from their normal age-matched
counterparts. The gliocentric shift coincides with a decline in
neurogenesis. This study describes a potential paradigm whereby
early changes in progenitor survival and phenotype could con-
tribute to and explain some of the underlying mechanisms giving
rise to the proliferative changes and impaired neuronal production
seen in the DS brain.
Results
Increased mitochondrial dysfunction, apoptosis, and
gliocentric progenitor pool shift in DS fetal brain and HNPs
While increased ROS, apoptosis and gliosis have been impli-
cated in postnatal DS neurons [3,12,13,14], few studies have
addressed whether the same endophenotypes are apparent during
cortical development. Our prior expression profiling studies and
network analyses suggest that dysregulated genes in DS HNPs
form functional clusters involved in redox states, cell death, and
glial characteristics [6]. To test these initial observations formally,
we asked whether these endophenotypes could be identified in
both tissue and HNPs from 14–21W GA DS frontal cortex. There
was a two-fold increase of apoptosis by TUNEL labeling along the
ventricular and subventricular zones (VZ/SVZ) in multiple 18W
GA DS frontal cortex. (Figure 1A). Several apoptotic cells
expressed ephrinB2 (Figure 1A, see lower panel, white
arrows), a marker for a subset of neural progenitors. Consistent
with the observation of increased vulnerability in DS HNPs in
vivo, this same accelerated rate of cell death could be appreciated
in vitro with neurospheres cultured from multiple DS HNP lines,
generated from 18W GA DS frontal cortex (Figure 1B). We also
observed an increase of GFAP expression in both DS fetal VZ/
SVZ tissue and HNPs of the same aged frontal cortices
(Figure 1C). To address the possible mitochondrial involvement
leading to the increased cell death and presumed glial progenitor
inflammatory response, we used a dual in situ labeling technique
that incorporated the MitoTracker Deep Red dye (a marker of
mitochondrial membrane potential) and MitoPY1 fluorescein dye
(a marker of mitochondrial H2O2 levels) [15] to simultaneously
track mitochondrial function and oxidative stress. Compared to
WT controls, the DS HNPs showed an increase of H2O2
production at the mitochondria and simultaneous decrease of
mitochondrial membrane potential (Figure 1D). The mitochon-
drial dysfunction, cell death, and adoption of more gliocentric
phenotypes in DS HNPs raised the possibility of impaired
neuronogenesis over time. We therefore examined the protein
expression for several neuronal and glial markers in 14W and 21W
GA fetal frontal cortex from both DS and WT controls. The
neuronal-restricted progenitor marker Pax6 [16] was strongly
expressed in 14W WT HNPs but absent in the 14W DS HNPs.
Appropriately at 21W GA (the end of corticogenesis), this marker
was still detectable in WT HNPs although at lower levels, but still
absent in the DS samples. We also found increased expression for
the glial progenitor markers GFAP and PDGFRA [17] in the DS
HNPs at both ages, relative to the WT HNPs (Figure 1E). The
cell fate change in DS was further confirmed by withdrawing
growth factor support for the HNPs and inducing differentiation of
these progenitors. Fluorescent immunostaining for different cell
fate markers and quantification of positively stained cells indicated
that DS HNPs underwent increased astrocytic and oligodendro-
cytic differentiation (with a corresponding reduction in neurogen-
esis), as compared with control HNPs (Figure S1). In summary,
these findings suggest that DS HNPs exhibit increased oxidative
stress and loss in membrane potential at the mitochondria,
undergo an increased rate of apoptosis, and show increased
gliocentric characteristics at the expense of neuronal phenotypes.
Elevated APP and S100B expression, reciprocal
regulation, and secretion in DS HNPs
Prior studies have shown that both HSA21-associated APP and
S100B levels increase in adult DS brain and that both these
proteins might play some role in DS progenitor development
[18,19]. Secretion of either APP or S100B has also been thought to
be neuroprotective at low concentrations but neurotoxic at high
concentrations [20,21]. These observations led to the possibility
that our novel observation of ongoing progenitor cell death seen
early in DS cortical development might be influenced by APP and
S100B either through activation of intracellular cell death
pathways or secretion of these soluble proteins, causing toxicity
to neighboring progenitors. We first examined whether upregula-
tion and colocalization of S100B and APP expression were
apparent in the VZ/SVZ regions of human DS fetal cortices.
Immunostaining for both S100B and APP showed overlapping,
elevated expression of both these proteins within progenitors along
the lateral ventricles of 18W GA forebrain (Figure 2A). The
upregulations of these two proteins in human DS cortex were also
appreciated by western blot analyses with a progressive increase
seen in 14W and 21W GA DS frontal cortex (Figure 2B). Second,
normal HNPs treated with soluble S100B protein showed
increased APP levels (Figure 2C) at concentrations (10ng/ml)
comparable to the levels secreted by DS HNPs (Figure 2F).
Similarly, overexpression of APP within HNPs through lentiviral
infection showed a consequent increase of cytoplasmic S100B
by western blot, and conversely transient overexpression of
S100B within HNPs demonstrated enhanced expression in APP
(Figure 2D). Furthermore, stimulation of HNPs with Ab42
caused a consequent dose-dependent increase of S100B expression
showed by western blot or soluble S100B secretion into the culture
media showed by ELISA (Figure 2E), suggestive of a reciprocal
synergistic effect. In these studies, we used the ZsGreen-APP
lentivirus (10 ml) and EGFP-S100B (5 mg) at doses (Figure S2A,
B) comparable to the levels of S100B and Ab42 secreted by DS
HNPs (Figure 2F, G). Third, Ab42 and Ab40 are the two most
common products of APP processing, but Ab42 is the more
fibrillogenic and thus associated with disease states [22]. We found
that S100B and Ab42 levels progressively increased within the
media of cultured DS progenitors by ELISA analyses and addition
of trypsin to the media led to degradation of these proteins,
indicating that secretion of the proteins likely contribute to effects
on cell viability [23] (Figure 2F, G). Fourth, S100B has
previously been shown to induce neuronal death through nitric
oxide [24] and we found that DS progenitors exhibited higher
levels of nitric oxide (Figure 2H). Collectively, these series of
experiments indicate that constitutive overexpression of HSA21-
associated S100B and APP/Ab42 could promote the pathological
expression of the other protein. Secretion of these proteins into the
S100B and APP in Down Syndrome
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local extracellular milieu even at fairly low levels (as compared to
levels required to induce neurotoxicity) in DS HNPs would
provide a basis for the observed increase in mitochondrial ROS
generation, apoptosis and gliocentric shift.
Elevated mitochondrial hydrogen peroxide, decreased
mitochondrial membrane potential and increased
apoptosis in HNPs due to S100B and APP
Elevated levels of secreted S100B or Ab42 would allow for the
proposed paracrine effects in neural progenitors- namely S100B
oversecretion leading to RAGE activation and mitochondrial
dysfunction with resulting ROS generation, and GSK3ß and tau
hyperphosphorylation [6]. APP could additively enhance this
pathological pathway by promoting S100B secretion and impair-
ing mitochondrial function. To address these possibilities, we
first transfected or infected normal HNPs with either a S100B
construct or an APP lentivirus in a dose dependent fashion and
observed a corresponding increase in S100B and Ab42 levels
within the cell medium. Furthermore, increases in S100B/Ab42 in
turn caused a decrease in mitochondrial function (Figure S2A,
B). Concurrent overexpression of both S100B and APP led to a
larger decline in mitochondrial function, suggestive of an additive
effect (Figure S2C). Given that S100B and Ab42 were secreted,
we examined whether exposure of HNPs to varying concentrations
of soluble S100B or Ab42 led to a dose dependent decline in
mitochondrial function. We used a dual in situ labeling of
MitoTracker Deep Red and MitoPY1 fluorescein dyes to track
simultaneously mitochondrial function and oxidative stress after
S100B/Ab42 treatment. Increasing concentrations of soluble
S100B or Ab42 resulted in dose dependent declines in mitochon-
drial respiration, as shown by the loss in rhodamine intensity, and
enhanced mitochondrial oxidative stress, as shown by the gain in
fluorescein intensity (Figure 3A, B). Concurrent S100B and Ab42
treatment also led to an additive decline in mitochondrial
membrane potential and increase in ROS (Figure S3E). Because
S100B and APP dependent loss of mitochondrial activity does
not necessary result in cell death, we wanted to determine the
functional outcome of the mitochondrial impairment due to
increased levels of these proteins. Thus, we examined the
consequent effects of soluble S100B or Ab42 on HNP viability.
We found a dose-dependent increase in apoptosis with overex-
pression of intracellular APP or S100B through lentiviral infection
or transient transfection into control HNPs (Figure S3A, B).
Again, co-overexpression of these proteins led to additive effects
(cell death) and the increase in cell death was not limited to
transfected cells (Figure S3C). Given our observations of S100B
and Ab42 secretion into the cell medium and the induction of cell
death with non-infected/transfected progenitors, we then asked
whether exposure of HNPs to progressively higher concentrations
of soluble S100B or Ab42 caused apoptosis. We observed a dose-
dependent increase in TUNEL labeling within HNPs following
incubation in the respective proteins (Figure 3C). To assess
whether the in vitro observations were similarly appreciated in vivo,
we examined the cortex of early postnatal (P0) trisomy 16
(Ts65Dn) mice, which have an extra copy of mouse APP but not
S100B. We found increased apoptosis in neural progenitors and
neurons within the early postnatal cortex of the Ts65Dn mice,
albeit to a lesser degree than in the human fetal cortex (Figure
S3D). To examine more directly the potential synergistic effects of
APP and S100B, we quantified the levels of ongoing cell death in
the hippocampus of APP (Tg2576) and APP/S100B (Tg2576-
huS100B) transgenic adult mice (19 months), and more specifically
the subgranular zone of hippocampus. Postnatally, this area is one
of the few regions in the central nervous system where neural
progenitors reside and exhibit continued neurogenesis, and
archival tissue from these mice would provide some indication of
in vivo effects due to these two proteins. We again appreciated
enhanced cell death with overexpression of both, as opposed to
overexpression of the individual proteins (Figure S3D). Taken in
sum, these observations provide a direct causal link between the
constitutive overexpression of HSA21-associated S100B and APP
(Ab42) and observed increase in mitochondrial ROS, decline in
membrane potentials and increase in apoptosis during neural
progenitor development.
S100B and APP/Ab42 promote gliocentric phenotypes in
HNPs and transgenic mice
Previous reports have implicated potential synergistic effects
between various RAGE ligands such as S100B and APP, leading
to gliosis [25]. Our prior studies have shown an increase in glial-
associated markers S100B and AQP4 within DS HNPs [6,9]. We
have also observed increased glial characteristics within the DS
HNP pool, as evidenced by the increased expression of proteins
such as GFAP in 18W GA human DS VZ/SVZ and correspond-
ingly, in cultured DS HNPs (Figure 1B). The possibility that these
altered progenitor phenotypes are due to APP and/or S100B
overexpression is supported at several levels. First, HNPs over-
expressing APP or S100B exhibited increased GFAP and
decreased MAP2 expression (Figure 4A). Second, HNPs exposed
to S100B or Ab42 dosed-dependently increased GFAP and
decreased MAP2 expression; concurrent exposure of S100B and
Ab42 enhanced GFAP and inhibited MAP2 expression synergis-
tically (Figure 4B). Third, the combinatorial effects of APP and
S100B in enhancing gliosis, previously appreciated in vitro, were
partly observed in vivo. In the cortical VZ of APP-overexpressing
early postnatal (P0) Ts65Dn mice, we observed increased
Figure 1. Increased apoptosis, gliosis, mitochondria dysfunction and gliocentric cell fate shift in DS HNPs. (A) Confocal fluorescence
photomicrographs demonstrate increased numbers of cells undergoing apoptosis as observed by TUNEL stain (rhodamine, counterstained with
Hoechst 33342) along the VZ for DS fetal cortex (18W GA, noted by white arrowheads). Higher magnification images are to the right. The relative
number of TUNEL labeled cells is quantified for both WT and DS VZ. (n = 4 for each). Many of the TUNEL positive cells (rhodamine) express the
ephrinb2 neural progenitor marker (fluorescein) along the VZ of 18W GA fetal cortex (see white arrowheads in lower panel). (B) The increase in
programmed progenitor cell death seen in vivo is also appreciated in vitro in human DS neurospheres after one week of culture. Quantification of
TUNEL-positive cells is below (n.5 neurospheres in each experimental sample). (C) Fluorescent photomicrographs demonstrate increased intensity
of immunostaining (rhodamine, counterstained with Hoechst 33342) for GFAP along the VZ of fetal 18W GA DS brain compared to normal age-
matched controls. Western blot confirms the increase. The upregulation of GFAP (rhodamine) is also found in the DS neurospheres derived from the
VZ of 18W GA fetuses after one week of culture, as shown by immunostaining and western blot. (D) Fluorescence photomicrographs by confocal
microscopy demonstrate increased intracellular mitochondrial H2O2 production showed by MitoPY1 (fluorescein) staining and disrupted
mitochondrial membrane potential showed by decreased MitoTracker deep red staining (rhodamine, counterstained with Hoechst 33342) within
DS HNPs compared to WT controls (18W GA) after 24 hours of culture. MitoPY1 localizes to the mitochondria and directly assays H2O2 levels in the
organelle. The quantification graphs are showed below. (E) Western blots demonstrate decreased neuroprogenitors shown by pax6 and increased
glioprogenitors showed by GFAP and PDGFRA staining in human DS frontal cortex (n = 3 age-matched control and DS fetal tissues, 14W and 21W GA).
Quantification is showed below. Scale bars are 200 mm for low magnification and 25 mm for high magnification in A, B and C, 25 mm for D. Data are
represented as mean +/2 STDEV, * p-value,0.05, ** p-value,0.01, *** p-value,0.001 by two tailed t-test.
doi:10.1371/journal.pone.0022126.g001
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expression of glial markers including S100B and GFAP within the
progenitor population along the ventricles of these mice
(Figure 4C, S4A). Increased oligoprogenitor marker PDGFRA
and decreased neuronal marker MAP2 expression were also
observed in Ts65Dn mice (Figure S4A). A similar gliocentric shift
was observed in the dentate gyrus of adult (19 months) APP
(Tg2576) and APP/S100B (Tg2576-huS100B) transgenic mice
with increased expression for GFAP, S100B, CNPase and MBP
(Figure 4D, S4B, S4C). These observations implicate a potential
cyclical path of neural progenitor injury whereby overexpression
Figure 2. Reciprocal up-regulation of secreted S100B, APP and oxidative stress in DS HNPs. (A) Fluorescent photomicrographs
demonstrate increased intensity of staining for both APP (rhodamine) and S100B (fluorescein, counterstained with Hoechst 33342) within DS neural
progenitors along the VZ of the 18W GA fetal cortex compared to normal age-matched controls. White arrowheads show the colocalizations of APP
and S100B along the VZ. (B) Western blot analyses confirm upregulation of both these proteins within the cortex of the DS brains of multiple
independent samples at an age dependent manner (n = 3 age-matched control and DS fetal tissues, 14W and 21W GA). (C) Incubation of S100B (10–
1000 ng/ml) for 24 hours in normal cultured HNPs dose-dependently increases APP levels; (D) S100B levels in the cytoplasm are increased with APP
overexpression for 4 days, and vice versa, as shown by western blot. (E) Western blot and ELISA assay show a dose-dependent increase in S100B
expression and secretion into the culture medium after Ab42 stimulation for 24 hours. (F) Longer term (1–2 weeks) culturing of DS HNPs results in a
progressive increase in the expression of S100B. The increased levels of S100B are largely due to soluble, extracellular S100B as trypsin treatment of
the media can degrade the protein. (G) A similar increase in Ab42 levels is appreciated in DS HNPs cultured over time. Increased levels of Ab42 are
also largely due to soluble, secreted protein that is degraded with trypsin treatment. Prior findings have shown that S100B or amyloid can lead to
increased ROS generation. Consistent with these findings, there is an increase of oxidative stress in DS HNPs, as showed by nitric oxide assays (H).
Scale bars are 12.5 mm in A; data are represented as mean +/2 STDEV, * p-value,0.05, ** p-value,0.01, *** p-value,0.001 by two tailed t-test.
doi:10.1371/journal.pone.0022126.g002
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Figure 3. Soluble S100B or Ab42 treatment promotes mitochondrial H2O2 production, loss in mitochondrial membrane potential
and apoptosis in normal cultured HNPs. (A) S100B exposure for 24 hours dose-dependently increases intracellular mitochondrial H2O2
production within HNPs, as shown by MitoPY1 (fluorescein, counterstained with Hoechst 33342) staining. MitoPY1 localizes to the mitochondria and
directly assays H2O2 levels in the organelle. S100B treatment also leads to mitochondrial dysfunction in a dose-dependent fashion, as showed by
S100B and APP in Down Syndrome
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of S100B and APP leads to mitochondrial impairment, cell death
and consequent inflammation with a shift toward gliocentric
phenotypes. This gliocentric shift would further promote mal-
adaptive responses due to S100B expression and activity, including
further accentuation of glial progenitor phenotypes.
RAGE blockade and APP inhibition in reversal of S100B
and APP effects in the DS phenotype
The effects of S100B and APP in DS could be due to disruption
of intracellular pathways, secretion and toxicity to neighboring
progenitors, or a combination of both mechanisms. We therefore
focused on RAGE blockade and APP inhibition to address the
contribution of paracrine effects from these proteins. The platelet
inhibitor, dalteparin sodium has been shown to have antagonizing
effects on RAGE activity [6,26]. As RAGE is the receptor for
S100B and Ab, we explored the therapeutic efficacy of these
agents on several levels. First, treatment of DS HNPs with anti-
RAGE antibody or dalteparin sodium resulted in a downregula-
tion of APP expression, as well as S100B and Ab42 secretion
(Figure 5A). Second, exposure of control HNPs to various
concentrations of soluble S100B (including the pathological dose
corresponding to 10 ng/ml secreted by DS HNPs) led to a
dose-dependent increase in H2O2 production as indicated by
increasing MitoPY1 fluorescein fluorescence. A similar dose-
dependent decrease in mitochondrial membrane potential was
seen, corresponding to a decline in MitoTracker deep red rho-
damine fluorescence. These pathological changes could be
reversed by pretreatment with either RAGE antibody or the
RAGE antagonist dalteparin sodium (Figure 5B, S5A). Third,
incubation of DS HNPs with anti-RAGE antibody or dalteparin
sodium resulted in an approximate 50% reduction in apoptosis as
gauged by TUNEL staining in the neurospheres; the levels were
still not back to age-matched WT baseline (Figure 5C, S5B).
Finally, parallel studies were performed to inhibit APP levels using
phenserine. Inhibition of the RAGE receptor (dalteparin sodium)
and APP (phenserine) provided further HNPs protection,
indicating that additional intracellular RAGE-independent mech-
anisms of cell injury also contribute to the observed phenotypes
(Figure 5D, 5E, 5F, S5C, S5D). Taken together, these
experiments suggest that the oxidative stress, mitochondrial
dysfunction, and consequential cell death apparent in DS HNPs
during development arise in part from soluble, secreted S100B and
Ab42 effects on the RAGE pathway.
Discussion
While various HSA21 genes have been implicated in oxidative
injury in DS, their cooperative interactions and consequent
effects have not really been explored within neural progenitors
during development and disease. Previous findings have suggest-
ed that APP and S100B may interact synergistically in con-
tributing to the neuronal dysfunction and injury. Adult double
transgenic (mutant APP (mAPP)/RAGE) mice demonstrated
increased activation of stress pathways (phosphorylation of p38
and JNK) and altered expression of markers of synaptic plasticity
(MAP kinases), leading to early abnormalities in spatial learning/
memory [27]. Additionally, adult brains from double transge-
nic (Tg2576/APP-huS100B) mice displayed augmented reactive
astrocytosis and microgliosis, high levels of S100 expression, and
increased levels of proinflammatory cytokines [28]. Neuronal
injury through APP is thought to enhance glial upregulation of
S100B and secretion of soluble S100B, thereby promoting further
neuronal injury. Increases in soluble APP, Ab42 and Ab42
antibody have been reported in the plasma of DS patients [29],
while our prior studies have shown that soluble S100B induces
p38 and JNK phosphorylation within DS neural progenitors [6].
The current studies now show a cooperative role for both these
proteins in DS neural progenitor injury early in development.
Both S100B and APP are constitutively overexpressed in DS
HNPs, expression of each protein directly enhances expression of
the other, and both proteins (S100B/A b42) appear to be
secreted. The extracellular effects of APP appear to result, in part,
from its processing to extracellular Ab42 possibly through RAGE,
which serves as a receptor for both S100B and Ab42 [30].
Presumably, the trisomy of the S100B and APP, initiates a
progressive cascade that further enhances the expression and
secretion of these individual proteins, activates the RAGE-
dependent pathway, and thereby additively promotes neural cell
death.
It is still unclear as to whether the decreased neuronal numbers
and hypotrophy in DS brains are due to increased cell death,
decreased proliferation, or more likely, a combination of both.
Several studies using early DS fetal brain samples and animal
models find that decreased proliferation of neural progenitors in
the ventricle or dentate gyrus play a dominant role in reducing
neuronal production [2,31,32]. However, oxidative stress has been
attributed to neuronal degeneration seen in later DS pathogenesis
[33,34]. Several studies using cultured DS neurons from fetal DS
brain also support an early increase in oxidative stress leading to
premature loss in neuronal viability [13,35]. We have previously
shown that constitutive overexpression of HSA21 associated
S100B in human DS neural progenitors leads to increased levels
of ROS and cell death in vitro [6,9]. The current work extends
these findings in demonstrating a synergistic effect between two
HSA21 genes, S100B and APP, in promoting oxidative stress, and
consequential cell death and gliosis both in vivo and in vitro. That
said, we also have observed a reduction in HNPs proliferation in
ventricular zone of DS frontal cortex (unpublished data). These
observations are consistent with Guidi’s report on the presence of
both increased apoptosis and reduced proliferation in the dentate
gyrus, hippocampus and parahippocampal gyrus of DS fetal brains
[3]. Finally, multiple studies have suggested different mechanistic
causes for the change in redox state in contributing to early neural
pathological changes in fetal DS brain [36]. In one report, HSA21
associated SOD1 is increased in fetal DS brain [37]. In another
report, the increased oxidative stress in fetal DS is suggested to be
the consequence of low levels of reducing agents and enzymes
involved in removal of hydrogen peroxide rather than overex-
pression of HSA21 associated SOD1 [38]. Overall, these collective
studies would indicate some role for both oxidative stress and cell
death, as well as a change in the proliferative rates of progenitor
pool, in promoting the reduction in DS brain size.
decreased MitoTracker deep red staining (rhodamine). Results are quantified graphically to the right. (B) A similar trend of increased intracellular
mitochondrial H2O2 and decreased mitochondrial membrane function appears after exposure to soluble Ab42 for 24 hours. The quantification graphs
for additive effects of S100B and Ab42 are showed in Figure S3E. (C) Exposure to S100B or Ab42 at concentrations comparable to that seen in DS
HNPs for 24 hours causes apoptosis (showed by TUNEL staining) in WT cultured HNPs. The graphs below show a dose-dependent increase in
apoptosis after S100B, APP or both S100B and APP stimulation (n.5 neurospheres in each experimental trial with at least 3 replicates). Scale bars are
25 mm for A and B; 200 mm for low magnification and 25 mm for high magnification in C; data are represented as mean +/2 STDEV, *** p-value,0.001
by two tailed t-test and one-way ANOVA.
doi:10.1371/journal.pone.0022126.g003
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Several studies suggest a primary role for Ab42, as opposed
to APP and Ab40, in the pathogenesis of DS. Ab42 deposition
has been observed in the cerebral tissue of DS subjects [39].
Expression levels also appear earlier than Ab40 accumulation
[40]. Furthermore, increases in soluble APP, Ab42 and Ab42
antibody have been found in the plasma of DS patients [29].
Figure 4. Gliocentric shift due to S100B and APP/Ab42 in DS HNPs. (A) Lentiviral infections of ZsGreen-APP or transfections of EGFP-S100B
constructs into normal HNPs for 4 days promote GFAP and inhibit MAP2 expression, as shown by western blot. (B) Pretreatment of normal, cultured
HNPs with increasing concentrations of soluble S100B or Ab42 for 24 hours shows a dose-dependent increase in GFAP and decrease in MAP2
expression. Co-treatment with S100B and Ab42 for 24 hours leads to an additive increase in GFAP and decrease in MAP2 expression levels. (C)
Quantification graphs from fluorescent photomicrographs (Figure S4A) in the cortex of early postnatal (P0) Ts65Dn mice show increased numbers
of immunostaining on glial markers such as S100B, GFAP and PDGFRA, and decreased numbers of neuronal staining with MAP2 compared to WT
(n = 3 for each group of mice). A similar increase appears in APP (Tg2576) or APP/S100B (Tg2576-huS100B) overexpressing mice compared to age-
matched WT control (Figure S4B and S4C). Data are represented as mean +/2 STDEV, * p-value,0.05, ** p-value,0.01, *** p-value,0.001 by two
tailed t-test and one-way ANOVA.
doi:10.1371/journal.pone.0022126.g004
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Lastly, inhibition of Ab42 production with a c secretase inhibitor
led to a reduction in APP induced neuronal apoptosis, which
suggests that soluble APP and Ab40 were not the primary cause of
neurotoxicity [41]. That said, some primary role for either
cytoplasmic or soluble APP or Ab40 may still contribute to the DS
phenotype and additional studies would be required to address
these possibilities.
Human neural progenitors are more susceptible to S100B and
Ab42 mediated toxicity as compared to neurons or astrocytes. We
observed cytotoxic effects of S100B and Ab42 at lower nanomolar
Figure 5. RAGE blocking and APP inhibition synergistically reduce oxidative stress, apoptosis and rescue sequential gliocentric cell
fate change in DS HNPs. (A) DS HNPs treated with Anti-RAGE antibody (1 mg/ml) or RAGE antagonist dalteparin sodium (1 IU/ml) for 24 hours
show reduced APP expression (left, western blot) and S100B or Ab42 secretion (right, ELISA). (B) Graphs show the S100B stimulation for 24 hours dose
dependently increase H2O2 production and decrease mitochondrial membrane potential which can be blocked by RAGE antibody (1 mg/ml) or
dalteparin sodium (1 IU/ml) (Figure S5A). (C) Quantification graph shows the large numbers of TUNEL+ cells in DS HNPs decrease to normal level
after Anti-RAGE antibody (1 mg/ml) or dalteparin sodium (1 IU/ml) treatment for 24 hours, and a quantification graph is on the upper left (n.5
neurospheres in each experimental sample) (Figure S5B). (D) DS HNPs are treated with dalteparin sodium and phenserine for 24 h, and quantitative
analyses of mitochondrial membrane potential and mitochondrial H2O2 fluorescent intensities are quantified from the photographs (Figure S5C) at
three separate dosages (A = dalteparin 0.01 IU/ml, phenserine 0.5 mM, or dalteparin 0.01 IU/ml+phenserine 0.5 mM; B= dalteparin 0.1 IU/ml,
phenserine 5 mM, or dalteparin 0.1 IU/ml+phenserine 5 mM; C=dalteparin 1 IU/ml, phenserine 50 mM, or dalteparin 1 IU/ml+phenserine 50 mM). The
graph shows a synergistic effect of the two drugs with a presumed level of toxicity at the highest concentrations. (E) Pretreatment with phenserine,
dalteparin or phenserine+dalteparin for 24 hours reduces GFAP and APP levels but increases MAP2 levels in DS HNPs. Western blot analyses show
significant reduction of GFAP and APP and increase of MAP2 expression levels following treatment. Band intensities are graphically quantified below.
(F) Quantification graph of TUNEL staining (Figure S5D) from DS HNPs treated with dalteparin sodium and phenserine for 24 hours shows
decreased TUNEL+ cells compared to controls (n.5 neurospheres in each experimental sample). Data are represented as mean +/2 STDEV,
* p-value,0.05, ** p-value,0.01, *** p-value,0.001 by one-way ANOVA.
doi:10.1371/journal.pone.0022126.g005
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to picomolar concentrations. The soluble Ab42 preparation used
in this study includes not only the fibrillar form but also oligomers,
which could be toxic to neurons in very low concentration [42,
43,44]. However, S100B is generally thought to have a neuro-
protective role at low concentrations within neurons or astrocytes,
but at higher micromolar concentrations causes cell death [21,
45,46]. The increased susceptibility of HNPs to lower concentra-
tions of S100B and APP may partially be attributable to the fact
that both proteins are already overexpressed within the same
progenitor cells (Figure 2A) - as opposed to the neuronal (APP)
and glial (S100B) paradigm seen in the adult brain. Moreover,
S100B and APP appear to increase mitochondrial hydrogen
peroxide levels directly, consistent with reports that APP/Ab
directly accumulate within and effect mitochondrial dynamics
[47,48]. Overall, the increased sensitivity of HNPs to these
proteins would only further augment the pathological processes
invoked from constitutive overexpression of S100B and APP in
DS cells.
A gliocentric shift in the progenitor pool would provide a
potential explanation for the preferential loss in later-born, pre-
sumptive GABA-ergic interneurons. Although cortical neuron
density appears normal in early gestation DS brain, neuronal
numbers decline at later (.23 weeks) gestational ages [49,50].
Prior studies have suggested that HSA21-associated DYRK1A
downregulates REST at a very early developmental stage, thereby
causing a skewed ratio of primitive endoderm at the expense of
neuroectodermal progenitors, leading to a reduction in neurogen-
esis [8]. This decline in neuronal production, however, would not
necessarily explain the cell type and age specific loss in GABA-
ergic neurons, as opposed to total neuronal numbers, in the DS
cortex [14]. More recent studies have suggested impairments in
interneuron development, potentially due to overexpression of a
transcription factor gene, COUP-TF1/NR2F1, although the
mechanism behind changes in this non-HSA21 associated tran-
scription factor in effecting interneurons is not clear [7]. The
current work now raises the possibility that ongoing neural
progenitor cell death from oxidative stress enhances gliocentric
progenitor characteristics at the expense of neuronal progenitor
phenotypes. This shift becomes more prominent later in cortical
development when the cyclical and synergistic roles played by such
inflammatory mediators such as S100B and APP become more
pronounced. Under this model, the loss in neuronogenic pro-
genitors would manifest later in development and thereby effect
interneuron production.
Several HSA21-dependent processes may contribute to the
overall reduction in neuronal numbers in the cortices of indi-
viduals with DS. First, we find that HNPs are more susceptible to
S100B and APP dependent mechanisms of cell injury and
constitutive overexpression of these genes in DS HNPs leads to
increased cell death. Second, inflammation as seen with induction
of the stress response kinases is known to promote glial
proliferation and reactive gliosis [51] and increased astrocytes or
glial phenotypes have been reported in DS brain [3]. We have
previously shown that S100B activates the JNK stress response
pathways [6] and now observe an increase in glial characteristics
within DS neural progenitors. This response to inflammatory
mediators appears to enhance proliferation of gliocentric progen-
itors at the expense of neuronal progenitors. This finding occurs
not only in HNPs in vitro, but also in TsDn65 or APP/S100B
transgenic mice in vivo. Third, HSA21-associated genes may
actually induce gliocentric phenotypes. For example, S100B is a
glial marker that promotes glial phenotypes whereas HSA21-
localized Olig2 is a transcription factor essential for development
of oligodendrocytes. The number of Olig2(+) progenitors increases
in the injured CNS, and Olig2(+) cells preferentially differentiate
into GFAP-expressing astrocytes, the main contributors to glial
scars which further secrete S100B [52,53]. This sequence of events
would further impair neuronogenesis. Fourth, glial progenitors
may be more resistant to the increased oxidative stressor [6], and
the increased ROS levels in DS may more readily compromise
neuronogenic progenitors.
In this study, we have characterized the neuropathological
phenotypes associated with early fetal DS cortex and HNPs. The
findings of increased ROS, mitochondrial dysfunction, cell death
and a glial shift in many ways mirrors the ongoing neurodegen-
eration and gliosis seen in the mature brain. Constitutively
overexpressed, contiguous genes along HSA21, including S100B
and APP, act in a synergistic manner to enhance secretion of these
proteins and activate the RAGE cascade. This pathway induces
mitochondrial hydrogen peroxide generation, loss of membrane
potential, and ultimately causes cell death. The ongoing inflam-
matory and stress response furthermore encourages HNPs to
adopt gliocentric characteristics, thereby not only enhancing this
cycle of cell injury but also surprisingly, impairing neurogenesis.
Finally, these studies suggest that the early defects in the
progenitor pool caused by various HSA21 genes will likely alter
the later stages of development - involving neuronal production
and viability, thereby amplifying and augmenting the MR and AD
seen in this disorder. More specifically, future studies will be
directed toward addressing whether this shift in progenitor
phenotype is responsible for the changes in proliferative rates
observed between normal and DS brains.
Materials and Methods
Human tissue, ethical and licensing considerations
The study has been approved by the Institutional Review Board
(IRB) at the Beth Israel Deaconess Medical Center (BIDMC) and
Brigham and Women’s Hospital. The de-identified human
discarded tissue was obtained from pathological samples during
autopsy. The tissue sections or neural progenitors from DS and
age-matched control brains (14–21W GA) were used in this study
for each of the experiments described. It is a discarded tissue
protocol and is exempt from informed consent, as determined by
the ethics and IRB review committee at BIDMC, and no informed
consent was obtained. The approved protocol number is 2004-P-
000299/5. The detail information of the tissues is listed in Table 1.
Transgenic mice
Archival brain sections from 19 months old transgenic mice
Tg2576 (APP over-expression) and Tg2576-huS100B (APP/
S100B over-expression) were provided by Dr. Takashi Mori
[28]. Trisomy16 mouse TsDn65 was obtained from The Jackson
Laboratory (Bar Harbor, Maine, USA). P0 brains were fixed with
4%PFA overnight, and frozen after 20% sucrose infiltration
overnight, 14 mm sections were collected for immunostaining. The
animal studies have been approved by the Institutional Animal
Care & Use Committee (IACUC) at the Beth Israel Deaconess
Medical Center. The approved IACUC protocol number for
animal work is 003-2011/100789.
Antibodies and reagents
Antibodies used for immunostaining, ELISA and western blot
analyses were as follows: Mouse anti-S100B (1:100 for ELISA and
1:500 for western blot, AbCam, Cambridge, UK), peroxidase-
conjugated anti-S100B (1:2000 for ELISA, AbCam, Cambridge,
UK), rabbit anti-S100B (1:200 for immunostaining and 1:1000 for
western blot, DAKO, Glostrup, Denmark), mouse anti-APP (1:100
S100B and APP in Down Syndrome
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for immunostaining, Millipore, Billerica, MA, USA), rabbit anti-
APP (1:1000 for western blot, gift of Professor Sam Gandy), goat
anti-Ephrin B2 (1:100, R&D, Minneapolis, MN, USA), mouse
anti-RAGE (1:1000, R&D, Minneapolis, MN, USA), mouse anti-
vinculin (1:1000, AbCam, Cambridge, MA, USA), rabbit anti-
GFAP (1:500 for immunostaining, and 1:2000 for western blot,
DAKO, Glostrup, Denmark), mouse anti-MBP (1:1000, Abcam,
Cambridge, MA, USA), mouse anti-CNPase (1:100, Millipore,
Billerica, MA, USA), mouse anti-Pax6 (Millipore, Billerica, MA,
USA), rabbit anti-olig2 (1:1000, gift of Professor Charles Stiles,
Dana-Farber Cancer Institute, Boston, MA, USA), mouse IgM
anti-O1 and O4 (1:50, gift of Professor Timothy Vartanian, Weill
Cornell Medical College, New York, USA), mouse anti-MAP2
(1:200 for immunostaining and 1:1000 for western blot, Sigma,
Saint Louis, MO, USA), rabbit anti-DCX (1:200, gift of Professor
Christopher Walsh, Children’s Hospital, Boston, MA, USA),
mouse anti-NeuN (1:200, Millipore, Billerica, MA, USA), rabbit
anti-GFP (1:1000, Abcam, Cambridge, MA, USA), and rabbit
anti-ZsGreen (1:1000, Clontech, Mountain View, CA, USA).
Reagents used for mitochondria and cell death studies are as
follows: MitoTracker Deep Red (Invitrogen, Carlsbad, CA, USA),
MitoPY1 (gift of Professor Christopher J. Chang, UC Berkeley,
CA, USA), In situ Cell Death Detection Kit, TMR red (Roche
Diognostics, Mannheim, Germany), Ab42 (American Peptide,
Sunnyvale, CA, USA), S100B (Calbiochem, San Diego, CA,
USA), Ab42 ELISA Kit (Invitrogen, Carlsbad, CA, USA),
phenserine ((3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethyl-
pyrrolo[2,3-b]indol-5-ol5-(N-phenylcarbamate), Tocris, Ellisville,
Missouri, USA) and RAGE antagonist dalteparin sodium
(Dalteparin sodium, Pfizer Inc, New York, USA), IFN-c was from
Pharmingen (Becton Dickinson, Italy).
Human neural progenitor cell cultures
Methods for VZ dissection and dissociation followed general
guidelines described previously [6,54]. In brief, samples were
obtained along the periventricular zone within the frontal cortex,
located by the landmark of Sylvian fissure and central fissure,
minced and washed in cold Hank’s buffered saline solution and
mechanically dissociated with pipettes. The samples were then
strained through a 40-mm cell strainer (Falcon, San Jose, CA,
USA). The dissociated cells were spun down, the media aspirated
and cells were placed in at low dilution (16106 per 5 ml) in
neurosphere medium (StemPro NSC SFM, Invitrogen, Carlsbad,
CA, USA) for expansion. The cultures were maintained in a
37uC/5% CO2 incubator for 1 to 2 weeks before the analysis. To
initiate differentiation, dissociated cells were plated on poly-D-
lysine/laminin 1-coated coverslips at a density of 16105 cells per
coverslip (24 mm624 mm). Oligodendrocyte differentiation was
achieved by maintaining the cells in KNOCKOUTTMDMEM/
F12 (Invitrogen, Main, MD)+2% B27(506, Invitrogen, Main,
MD)+10 ng/ml bFGF (R&D, Minneapolis, MN, USA)+100 ng/
ml SHH (R&D, Minneapolis, MN, USA)+10 ng/ml PDGF-AA
(R&D, Minneapolis, MN, USA) for 2 days, then switching to the
same medium without growth factors for another 5 days. Neuronal
differentiation was achieved by maintaining cells in KNOCK-
OUTTMDMEM/F12 +2% B27 (506) for 7 days. Astrocyte
differentiation was done by culturing cells in KNOCKOUTTMD-
MEM/F12 +1%FBS for a week. The pharmacological treatments
were in the same neurosphere medium without EGF and bFGF.
The preparation of Ab42 was as follows, Ab42 was dissolved with
distilled water to make 10 mg/ml stock solutions, and put into
37uC incubator for 24 h before further dilution and use.
Constructs, viral production and transfection or infection
pEGFP-C1-S100B and pHAGE-CMV-MCS-IZsGreenW-APP
constructs were made for in vitro overexpression experiments.
Human S100B full-length cDNA sequence was cloned into
pEGFP-C1 vector with XhoI/Hind III cutting site. The trans-
fection of pEGFP-C1-S100B construct in dissociated neural
progenitors was performed using Transfectin (Bio-Rad, Hercules,
CA, USA) according to the company’s product instruction.
Human APP full length cDNA sequence were cloned into
pHAGE-CMV-MCS-IZsGreenW vector (gift of The Harvard Gene
Therapy Initiative) with NotI/XbaI cutting site; Production of
lentiviruses was done in 293T cells as described by Richard
Mulligan’s lab [55,56], the MOI of 1 is used for both viruses.
Dissociated neural progenitor cells were infected with lentivirus or
transfected with constructs carrying the target genes, and kept in
neural stem cell medium for 4 days before analysis.
Immuno-staining and TUNEL analyses
Tissue sections after antigen retrieval or fixed cells were placed
in blocking solution with PBS containing 3% goat serum,
incubated overnight in the appropriate antibody, and processed
through standard fluorescent secondaries (CY2, CY3, Jackson
Immunoresearch Laboratories, Westgrove, PA, USA, and FITC,
Sigma, 1:500). Specimens were examined using confocal fluores-
cence microscopy after mounting in appropriate media. Apoptosis
were detected in sections or neurospheres by TUNEL using In
Situ Cell Death Detection Kit, TMR red (Roche). Sections with
positive stained cells were counted in at least three sections for
each patient and 4 patients for each assay. Cells staining positive
for expressed markers were counted in five randomly chosen
microscopic fields (0.02 mm2; magnification: 6306) along the
ventricular lining in each object; 5–10 neurospheres were sampled
on each treatment or patient, the TUNEL positive cells were
Table 1. Aborted fetal brain tissue used in this study.
Gestational Age Karyotype Gender Postmortem Interval
14 weeks 46, XX Female 3 hours
14 weeks 46, XX Female 4 hours
14 weeks 46, XY Male 2 hours
14 weeks 47, XX, +21 Female 2 hours
14 weeks 47, XX, +21 Female 3 hours
14 weeks 47, XY, +21 Male 3 hours
18 weeks 46, XY Male 3 hours
18 weeks 46, XY Male 3 hours
18 weeks 46, XY Male 2 hours
18 weeks 46, XX Female 3 hours
18 weeks 46, XX Female 4 hours
18 weeks 46, XY, +21 Male 3 hours
18 weeks 46, XY, +21 Male 4 hours
18 weeks 46, XY, +21 Male 2 hours
18 weeks 46, XX, +21 Female 3 hours
18 weeks 46, XX, +21 Female 2 hours
21 weeks 46, XX Female 4 hours
21 weeks 46, XX Female 3 hours
21 weeks 46, XY Male 3 hours
21 weeks 47, XX, +21 Female 3 hours
21 weeks 47, XX, +21 Female 2 hours
21 weeks 47, XY, +21 Male 3 hours
doi:10.1371/journal.pone.0022126.t001
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counted against the total cells in the field randomly selected.
TUNEL positive cells and immuno-positive cells in mouse sections
were counted in cortex or dentate gyrus area (0.02 mm2; mag-
nification: 6306) of equal location, at least three sections for each
mouse and three mice for each group.
Western blot
Proteins were extracted from neurospheres or cell lines by
previously described methods [6,9]. Briefly, cells were solubilized in
lysis buffer, separated on a 7.5% SDS–PAGE gel and transferred
onto PVDF membrane. The membrane was probed with the
appropriate antibody and detected by enhanced chemiluminescence.
ELISA assay
Enzyme-linked immunosorbent assay (ELISA) for S100B was
carried out on tissue supernatants as well as in the cell lysates.
Briefly, 15 mL of sample plus 15 mL of Tris buffer were applied on
a microtitre plate previously coated with monoclonal anti-S100B
(1:1000; AbCam) in carbonate buffer and blocked with 1% bovine
serum albumin. After washing, peroxidase-conjugated anti-S100B
(1:2000; AbCam) was added and incubation continued for 1 h.
The plate was washed, 0.2 mL of peroxidase substrate (Fast OPD;
Sigma, Milan, Italy) was added and the plate was incubated for a
further 30-min period in the dark. Absorbance was measured at
450 nm on a microtitre plate reader. S100B levels in the samples
were determined using a standard curve of S100B and expressed
as ng/mL. Ab42 ELISA was carried out with Ab42 ELISA kit
(Invitrogen, Carlsbad, CA, USA) following the company’s protocol.
Nitric oxide assay
Nitric Oxide (NO) production was measured as the stable
metabolite nitrite (NO2
2) accumulated in the incubation medium
of neural progenitor cells after 24 hours following LPS + IFN-c
addition, using a spectrophotometric assay based on Griess reac-
tion as previously [57].
MitoTracker deep red and MitoPY1 assay
The neurospheres or attached neural progenitor cells after
treatments were incubated with 0.5 mM MitoTracker deep red
(Invitrogen M22426, Carlsbad, CA, USA) together with 5 mM
MitoPY1 for 30 min in 37uC/5% CO2 incubator. MitoPY1 is a
mitochondrial-targeted fluorescent probe that responds to hydro-
gen peroxide by a turn-on increase in fluorescence intensity [15].
The cells were then fixed with 4% paraformaldehyde for 10 min,
and wash with PBS, counterstained with Hoechst 33342 (Invitro-
gen, Carlsbad, CA, USA). Cells were mounted on slides and
scanned by fluorescence microscope. The intensity of staining was
measured in 10 randomly chosen cells from each of nine neuro-
spheres or wells by each treatment. The numbers of MitoPY1
stained granules were counted in each case.
Statistical analyses
Results were expressed as the mean +/2 STDEV of n
experiments. Statistical analysis was performed with Student’s T
test or one way ANOVA, with P,0.05 considered significant.
Supporting Information
Figure S1 Gliocentric cell fate shift within human fetal
DS HNPs. Immunostaining of WT and DS HNPs show shifted
cell fates after differentiation for 1 week. The glial cells are stained
with O1 (rhodamine), O4 (rhodamine), CNPase (fluorescein),
S100B (fluorescein), MBP (rhodamine), Olig2 (fluorescein) and
GFAP (rhodamine); the neuronal cells are stained with MAP2
(fluorescein), DCX (fluorescein) and NeuN (fluorescein). The
quantification graph showing decreased neuronal cells and
increased glial cells in DS HNPs differentiation compared to
WT controls are showed to the right. Scale bar is 25 mm. Data are
represented as mean +/2 STDEV, ** p-value,0.01, *** p-value
,0.001 by two tailed t-test.
(TIF)
Figure S2 Intracellular over-expression of S100B and
APP cause loss of mitochondrial membrane potential.
(A) APP-lentiviral infection of WT HNPs dose-dependently
decreases MitoTracker deep red (rhodamine) intensities 2 days
after infection, with infected cells in fluorescein. The increased
expression of APP and secretion of Ab42 are showed on the right
by western blot and ELISA. (B) EGFP-S100B transfection of WT
HNPs shows a similar pattern as that in APP-lentiviral infections
48 hours after transfection. The increased expression and secre-
tion of S100B are showed to the right by western blot and ELISA.
(C) A combination of APP-lentiviral infection and EGFP-S100B
transfection for 2 days in HNPs shows an additive effect in
reducing the mitochondrial membrane potential. Scale bars are
25 mm in A, B and C; data are represented as mean +/2 STDEV,
* p-value,0.05, *** p-value,0.001 by two tailed t-test and one-
way ANOVA.
(TIF)
Figure S3 Intracellular over-expression of S100B and
APP cause increased apoptosis in HNPs and transgenic
mice. (A) APP-lentiviral infection of WT HNPs dose-dependently
increases TUNEL positive staining (rhodamine) 4 days after
infection, with infected cells in fluorescein. Graphical quantifica-
tion is to the right. (B) EGFP-S100B transfection of WT HNPs
shows a similar pattern as that in APP-lentiviral infection 4 days
after transfection. Graphical quantification is to the right. (C) A
combination of APP-lentiviral infection and EGFP-S100B trans-
fection in WT HNPs for 4 days shows an additive effect of
increasing apoptosis. (D) TUNEL staining with detection under
rhodamine fluorescence shows increased labeling of cells in the
frontal cortex of Ts65Dn mice compared to WT control (left
panel, n = 3 for each group of mouse). The increased TUNEL
labeling of cells are also found in the subgranular zone of dentate
gyrus of 19 months old APP (Tg2576) or APP/S100B (Tg2576-
huS100B) over-expression mice compared to WT control (right
panel, n = 4 for each group of mouse). The quantification graphs
are below. (E) Quantification graphs show additive effects of
S100B and Ab42 in enhancing the observed mitochondrial
dysfunction 24 hours after treatment (Figure 3B). Scale bars
are 200 mm for low magnification and 25 mm for high magnifi-
cation in A, B, C and D; data are represented as mean +/2
STDEV, * p-value,0.05, ** p-value,0.01, *** p-value,0.001 by
two tailed t-test and one-way ANOVA.
(TIF)
Figure S4 Intracellular over-expression of S100B and
APP promote gliocentric phenotypes. (A) Fluorescent
photomicrographs in the cortex of early postnatal (P0) Ts65Dn
mice show increased numbers of immunostaining on glial markers
such as S100B (fluorescein, upper left panel), GFAP (rhodamine,
upper right panel) and PDGFRA (rhodamine, lower left panel)
compared to WT controls. There is also a decreased numbers of
immunostaining on neuronal marker MAP2 (rhodamine, lower
right panel) in Ts65Dn mice compared to WT controls. The white
arrowheads in low magnification figures mark the VZ in frontal
cortex; the high magnification figures show cells in VZ except for
MAP2 in cortical plate. (B) Fluorescent photomicrographs of
S100B (rhodamine, left panel) and GFAP (rhodamine, right panel)
S100B and APP in Down Syndrome
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staining (counterstained with Hoechst 33342) in the cortex of 19
months old mice show increased apoptosis and gliosis in APP
(Tg2576) or APP/S100B (Tg2576-huS100B) over-expressing mice
compared to WT control. Increased rhodamine stained cells are
counted in the subgranular zone of dentate gyrus, with the
quantification of immuno-positive cells showed below (n= 4 for
each group of mice). (C) Fluorescent photomicrographs of CNPase
(rhodamine, left panel) and myelin basic protein (MBP, rhoda-
mine, right panel) staining (counterstained with Hoechst33342) in
the cortex of 19 months old mice shows increased expression of
two oligodendrocyte markers in the APP (Tg2576) or APP/S100B
(Tg2576-huS100B) over-expressing mice compared to WT
control. Intense rhodamine fluorescence is seen in the subcortex
and subhippocampus (n = 4 for each group of mice). Scale bars are
200 mm for low magnification and 25 mm for high magnification
in A, B and C.
(TIF)
Figure S5 RAGE blocking and APP inhibition synergis-
tically reduce oxidative stress and apoptosis. (A) Photo-
graphs show the S100B dose dependently increase H2O2
production shown by MitoPY1 staining (fluorescein) and decrease
mitochondrial membrane potential shown by MitoTracker deep
red staining (rhodamine), which can be blocked by RAGE
antibody or dalteparin sodium after 24 hours. (B) The large
numbers of TUNEL+ cells in DS HNPs decrease to normal level
after Anti-RAGE antibody or dalteparin sodium treatment for
24 hours. (C) Fluorescent photomicrographs of DS HNPs show a
dose-dependent rise in mitochondrial membrane potential, as
evidenced by an increase in MitoTracker deep red staining
(rhodamine) after 24 hours treatment with RAGE and APP
inhibitors. A corresponding decrease in mitochondrial hydrogen
peroxide levels is also apparent, as evidenced by MitoPY1 staining
(fluorescein). (D) The number of TUNEL positive, DS HNPs are
decreased after pretreatment with the RAGE antagonist dalte-
parin sodium, APP inhibitor phenserine, or both (dalteparin
sodium + phenserine) for 24 hours. Scale bars are 25 mm in A and
C, 200 mm for low magnification and 25 mm for high magnifica-
tion in B and D.
(TIF)
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